Overview

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Status:
Completed
Trial end date:
2018-01-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of SL-701 as a treatment for recurrent glioblastoma multiform (GBM).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Stemline Therapeutics, Inc.
Treatments:
Bevacizumab
Carboxymethylcellulose Sodium
Poly I-C
Poly ICLC
Vaccines